These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 12134945

  • 1. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
    Tang F, Horie K, Borchardt RT.
    Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME, Podila L, Ely D, Almeida I.
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [Abstract] [Full Text] [Related]

  • 4. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
    Tang F, Borchardt RT.
    Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
    Tang F, Borchardt RT.
    Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
    [Abstract] [Full Text] [Related]

  • 6. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
    Horie K, Tang F, Borchardt RT.
    Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
    [Abstract] [Full Text] [Related]

  • 7. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
    Zhang Y, Benet LZ.
    Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
    [Abstract] [Full Text] [Related]

  • 8. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D, Harder A, Fang Z, Weinheimer M, Laplanche L, Mezler M.
    Pharm Res; 2020 Sep 11; 37(10):194. PubMed ID: 32918191
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
    Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC.
    Pharmacotherapy; 2003 Apr 11; 23(4):436-42. PubMed ID: 12680473
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K, Sane R, Podila L, Taub ME.
    J Pharm Sci; 2012 May 11; 101(5):1888-97. PubMed ID: 22359351
    [Abstract] [Full Text] [Related]

  • 12. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
    Nies AT, Herrmann E, Brom M, Keppler D.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb 11; 376(6):449-61. PubMed ID: 18157518
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the IPEC-J2 MDR1 (iP-gp) cell line as a tool for identification of P-gp substrates.
    Ozgür B, Saaby L, Langthaler K, Brodin B.
    Eur J Pharm Sci; 2018 Jan 15; 112():112-121. PubMed ID: 29146563
    [Abstract] [Full Text] [Related]

  • 14. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, Zhou SF.
    Curr Drug Metab; 2007 May 15; 8(4):325-40. PubMed ID: 17504222
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R, Jadhav G, Vangala S.
    Curr Pharm Biotechnol; 2017 May 15; 18(14):1151-1158. PubMed ID: 29521222
    [Abstract] [Full Text] [Related]

  • 16. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
    Lumen AA, Li L, Li J, Ahmed Z, Meng Z, Owen A, Ellens H, Hidalgo IJ, Bentz J.
    PLoS One; 2013 May 15; 8(8):e69394. PubMed ID: 23976943
    [Abstract] [Full Text] [Related]

  • 17. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
    Ozgür B, Saaby L, Janfelt C, Langthaler K, Eneberg E, Jacobsen AM, Badolo L, Montanari D, Brodin B.
    Eur J Pharm Biopharm; 2021 Dec 15; 169():211-219. PubMed ID: 34756975
    [Abstract] [Full Text] [Related]

  • 18. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells.
    Balimane PV, Chong S, Patel K, Quan Y, Timoszyk J, Han YH, Wang B, Vig B, Faria TN.
    Arch Pharm Res; 2007 Apr 15; 30(4):507-18. PubMed ID: 17489369
    [Abstract] [Full Text] [Related]

  • 19. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
    Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W.
    Br J Pharmacol; 2010 Jul 15; 160(6):1453-63. PubMed ID: 20590635
    [Abstract] [Full Text] [Related]

  • 20. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
    Patel J, Buddha B, Dey S, Pal D, Mitra AK.
    Am J Ther; 2004 Jul 15; 11(4):262-77. PubMed ID: 15266218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.